• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Viswanadhan Krishnan

    3/7/25 4:15:46 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGIO alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Viswanadhan Krishnan

    (Last) (First) (Middle)
    88 SIDNEY STREET

    (Street)
    CAMBRIDGE MA 02139

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/05/2025
    3. Issuer Name and Ticker or Trading Symbol
    AGIOS PHARMACEUTICALS, INC. [ AGIO ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Corp Dev & Strategy
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    No securities are beneficially owned.
    /s/ William Cook, as Attorney in Fact for Krishnan Viswanadhan 03/07/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AGIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AGIO

    DatePrice TargetRatingAnalyst
    2/24/2025$58.00Buy
    H.C. Wainwright
    10/16/2024Sector Outperform
    Scotiabank
    10/10/2024$51.00Outperform
    Raymond James
    9/27/2024$60.00 → $56.00Outperform → Market Perform
    Leerink Partners
    2/8/2024Overweight
    Cantor Fitzgerald
    2/3/2023$41.00Overweight
    Piper Sandler
    11/17/2022$17.00 → $32.00Sell → Neutral
    Goldman
    7/27/2022$33.00Mkt Perform → Outperform
    SVB Leerink
    More analyst ratings

    $AGIO
    SEC Filings

    See more
    • SEC Form S-8 filed by Agios Pharmaceuticals Inc.

      S-8 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)

      6/18/25 4:41:20 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Agios Pharmaceuticals Inc.

      8-K - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)

      6/18/25 4:31:14 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Agios Pharmaceuticals Inc.

      SCHEDULE 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

      6/13/25 2:50:40 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Capello Jeffrey D converted options into 1,977 shares, increasing direct ownership by 100% to 3,953 units (SEC Form 4)

      4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

      6/17/25 4:16:37 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Owen Adams Catherine converted options into 1,977 shares, increasing direct ownership by 100% to 3,953 units (SEC Form 4)

      4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

      6/17/25 4:15:10 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Fouse Jacqualyn A converted options into 15,933 shares and sold $194,172 worth of shares (7,497 units at $25.90), increasing direct ownership by 6% to 149,220 units (SEC Form 4)

      4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

      4/10/25 4:02:58 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for PYRUKYND issued to AGIOS PHARMACEUTICALS INC

      Submission status for AGIOS PHARMACEUTICALS INC's drug PYRUKYND (ORIG-1) with active ingredient MITAPIVAT has changed to 'Approval' on 02/17/2022. Application Category: NDA, Application Number: 216196, Application Classification: Type 1 - New Molecular Entity

      2/17/22 2:39:08 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for TIBSOVO issued to AGIOS PHARMS INC

      Submission status for AGIOS PHARMS INC's drug TIBSOVO (SUPPL-7) with active ingredient IVOSIDENIB has changed to 'Approval' on 03/18/2021. Application Category: NDA, Application Number: 211192, Application Classification: Labeling

      3/22/21 5:06:31 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care